氯喹联合放疗提高恶性脑肿瘤放射敏感性:系统综述
该系统综述纳入13项临床研究共789例患者,评估氯喹(CQ)或其类似物联合放疗治疗高级别胶质瘤(HGG)与脑转移瘤的安全性和疗效。HGG的8项对照试验中仅3项报告显著获益,中位生存期7.9至36.6个月;脑转移瘤仅1项研究报告无进展生存期显著改善。辅助CQ不良事件多为轻度,但多数研究使用低剂量且长期安全性不确定。
要点
- HGG中CQ联合放疗的生存获益有限且不一致,8项对照试验仅3项报告显著获益
- 脑转移瘤证据有限,仅1项研究报告无进展生存期显著改善
- 不良事件多为轻度,但多数研究采用低剂量CQ,长期安全性尚不明确
核心结论
- 对HGG,CQ联合放疗显示出一定前景但生存获益有限且不一致。
- 对脑转移瘤,证据有限且较不理想,跨肿瘤类型和研究设计均无一致获益。
- 不良事件总体轻微,但多数研究使用低CQ剂量,长期安全性仍不确定。
研究设计与样本
- 系统综述,检索PubMed、Embase、Scopus和Web of Science数据库,无日期限制。
- 纳入评估CQ或其类似物联合放疗治疗HGG或脑转移瘤并报告总生存期(OS)结局的英文临床研究(n≥5例患者)。
- 排除临床前研究和综述,最终纳入13项符合条件的研究,共789例患者。
主要发现
- HGG和脑转移瘤中,CQ中位剂量为每日250 mg,全脑放疗是最常见的放疗方式。
- HGG的8项对照试验中3项报告治疗显著获益,中位生存期为7.9至36.6个月。
- 脑转移瘤仅1项研究报告相对对照显著改善无进展生存期。
- 辅助CQ的安全性总体良好,两类患者人群中报告的不良反应均为轻度。
关键数值与推荐
- 纳入标准:英文临床研究、n≥5例患者、评估CQ或其类似物联合放疗治疗HGG或脑转移瘤、报告OS结局。
- 排除标准:临床前研究和综述。
- CQ中位剂量为每日250 mg。
临床怎么用
- HGG患者可考虑CQ联合放疗,但需告知生存获益证据有限且不一致。
- 脑转移瘤不推荐常规使用CQ联合放疗,因缺乏一致获益证据。
- 使用CQ时关注不良反应,多数研究采用低剂量,长期安全性需进一步评估。
局限性
- 多数研究使用低CQ剂量,长期安全性仍不确定。
- 脑转移瘤证据有限,跨肿瘤类型和研究设计均无一致获益。
- HGG对照试验结果不一致,仅3/8报告显著获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Chloroquine (CQ) has been studied for over 50 years as a potential adjuvant to cancer therapy. However, clinical studies investigating CQ combined with radiotherapy for brain tumors have yielded conflicting results. We aimed to synthesize existing evidence on the safety and efficacy of adjuvant CQ with radiotherapy for treatment of high-grade gliomas (HGG) and brain metastases. METHODS: We conducted a systematic review using the PubMed, Embase, Scopus, and Web of Science databases with no date restrictions. We included English-language clinical studies (n ≥ 5 patients) that evaluated the combination of CQ or its analogues with radiotherapy for HGG or brain metastases and reported overall survival (OS) outcomes. Pre-clinical studies and reviews were excluded. RESULTS: We identified 13 eligible studies with 789 patients. Across both HGG and brain metastases, the median CQ dose was 250 mg daily, with whole-brain radiotherapy as the most common radiotherapy modality. For HGG, 3 out of 8 controlled trials reported significant benefit from treatment, with median survival ranging from 7.9 to 36.6 months. By comparison, only a single study of brain metastases found significantly improved progression-free survival relative to control. The safety profile of adjuvant CQ was generally favorable, with mild adverse effects reported in both patient populations. CONCLUSIONS: For HGG, CQ combined with radiotherapy shows promise but modest, inconsistent survival benefits. For brain metastases, evidence is limited and less favorable, with no consistent benefit across tumor types or study designs. Adverse events are generally mild, though most studies used low CQ doses and long‑term safety remains uncertain.
引用
- Harary PM, Hori YS, Annagiri S, et al. Enhancing radiation sensitivity in malignant brain tumors with chloroquine: a systematic review. J Neurooncol. 2025. PMID: 41348255. doi:10.1007/s11060-025-05362-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。